Lyophilized semaglutide is the freeze-dried powder form of the GLP-1 receptor agonist peptide semaglutide, supplied in sealed vials for research use. Unlike the pre-mixed injectable pens (Ozempic, Wegovy) or oral tablets (Rybelsus) manufactured by Novo Nordisk for clinical use, lyophilized semaglutide is a raw research peptide that must be reconstituted with bacteriostatic water before use in laboratory settings.
For researchers studying GLP-1 receptor signaling, metabolic pathways, or incretin biology, the lyophilized form offers advantages over pharmaceutical preparations — it allows precise custom concentrations, is more stable in long-term storage, and is available without a prescription for legitimate research purposes. This guide covers the molecular properties, reconstitution protocols, stability characteristics, and key research considerations for working with lyophilized semaglutide. Retatrutide for sale straight from our store which is another popular GLP-1 peptide.
Research Use Only Disclaimer: Semaglutide is the active ingredient in FDA-approved medications (Ozempic, Wegovy, Rybelsus). Lyophilized semaglutide sold by research peptide suppliers is intended for laboratory research only and is not a substitute for prescribed medications. VMAX Peptides does not sell or market semaglutide as a pharmaceutical product. Consult a healthcare provider for any medical questions about semaglutide therapy.
| Property | Detail |
| Full Name | Semaglutide |
| Classification | GLP-1 receptor agonist (incretin mimetic) |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4,113.6 Da |
| Amino Acid Length | 31 amino acids (modified GLP-1 analog) |
| Key Modification | C-18 fatty diacid chain at Lys-26 (enables albumin binding) |
| Half-Life | ~7 days (due to albumin binding and DPP-4 resistance) |
| CAS Number | 910463-68-2 |
| Storage (Lyophilized) | -20°C (freezer) for long-term; 2-8°C acceptable |
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone released by the gut after eating. Natural GLP-1 has a half-life of only 2–3 minutes because it is rapidly degraded by the enzyme DPP-4 (dipeptidyl peptidase-4). Semaglutide incorporates two key structural modifications that extend its half-life to approximately 7 days.
First, an amino acid substitution at position 8 (Ala→Aib) renders semaglutide resistant to DPP-4 degradation. Second, a C-18 fatty diacid chain attached at position 26 (Lys-26) enables reversible binding to serum albumin — the most abundant protein in blood plasma. This albumin binding acts as a circulating reservoir, slowly releasing active semaglutide over days rather than minutes.
When semaglutide binds to GLP-1 receptors, it triggers several downstream effects that have been extensively studied. It stimulates glucose-dependent insulin secretion from pancreatic beta cells. It suppresses glucagon release, reducing hepatic glucose output. It slows gastric emptying, reducing the rate at which food moves from the stomach to the small intestine. And it acts on hypothalamic GLP-1 receptors to reduce appetite and increase satiety signaling.
This multi-pathway activity is the basis for semaglutide’s clinical use in both type 2 diabetes management and weight management — the two indications for which it has received FDA approval under the brand names Ozempic, Wegovy, and Rybelsus.
| Feature | Lyophilized Semaglutide (Research) | Pharmaceutical Semaglutide (Ozempic/Wegovy) |
| Form | Freeze-dried powder in vial | Pre-mixed liquid in auto-injector pen |
| Preparation | Requires reconstitution with BAC water | Ready to use — no preparation needed |
| Concentration | Custom — determined by reconstitution volume | Fixed — 0.25, 0.5, 1.0, or 2.0 mg/dose |
| Storage stability | 24+ months lyophilized at -20°C | ~56 days in pen after first use |
| Regulatory status | Research use only — not FDA approved in this form | FDA approved (Ozempic, Wegovy, Rybelsus) |
| Prescription required | No (sold as research peptide) | Yes |
| Purity verification | COA with HPLC/MS testing | Pharma-grade manufacturing (cGMP) |
It is critical to understand that lyophilized semaglutide sold by research peptide suppliers is not the same product as Ozempic or Wegovy. While the active molecule is identical (semaglutide), the manufacturing process, quality control standards, formulation excipients, and regulatory oversight differ significantly. Research peptide semaglutide has not undergone the same clinical validation, cGMP manufacturing processes, or FDA review as the pharmaceutical products. VMAX Peptides sells lyophilized semaglutide strictly as a research compound.
The reconstitution process for lyophilized semaglutide follows the same core protocol as other research peptides, but the longer half-life of semaglutide means vials tend to last longer before needing replacement, making proper reconstitution and storage particularly important.
Step 1: Swab the rubber stopper of both the semaglutide vial and the bacteriostatic water vial with 70% isopropyl alcohol swabs. Allow to dry for 10–15 seconds.
Step 2: Using a syringe, draw the desired volume of bacteriostatic water (typically 2mL for a 5mg vial, yielding a concentration of 2,500mcg/mL, or 2.5mg/mL).
Step 3: Insert the needle through the semaglutide vial stopper and angle it so water runs down the inside wall of the vial. Depress the plunger slowly — do not squirt directly onto the peptide cake.
Step 4: Allow the peptide to dissolve. Gently swirl or roll the vial between your palms. Do not shake. Semaglutide typically dissolves completely within 2–5 minutes. The resulting solution should be clear and colorless.
Step 5: Label the vial with the concentration, reconstitution date, and use-by date (28 days). Store at 2–8°C (refrigerator). Never freeze.
| Vial Size | BAC Water Added | Concentration | mcg Per 10 Units (0.1mL) |
| 3mg | 1.5mL | 2,000 mcg/mL | 200 mcg |
| 5mg | 2mL | 2,500 mcg/mL | 250 mcg |
| 5mg | 1mL | 5,000 mcg/mL | 500 mcg |
| 10mg | 2mL | 5,000 mcg/mL | 500 mcg |
Need a different concentration? Use our peptide reconstitution calculator to find the exact BAC water volume for your target dose.
For the complete reconstitution process, see peptide reconstitution guide.
Lyophilized semaglutide is highly stable when stored correctly. In sealed vials at -20°C (freezer), stability exceeds 24 months with minimal potency loss. At 2–8°C (refrigerator), stability is typically 6–12 months. The peptide tolerates brief periods at room temperature during shipping without significant degradation.
Reconstituted semaglutide in bacteriostatic water should be stored at 2–8°C and used within 28 days. Semaglutide’s lipid modification (the C-18 fatty diacid chain) adds some additional stability compared to unmodified peptides, but the standard 28-day reconstituted shelf life should still be observed.
The most important storage rule applies to semaglutide as to all reconstituted peptides: never freeze the reconstituted solution. Ice crystal formation damages the peptide’s tertiary structure and the critical albumin-binding fatty acid chain, resulting in permanent loss of the extended half-life that makes semaglutide unique.
For detailed storage advice, see peptide storage guide
Semaglutide is one of the most actively researched peptides in the world, with ongoing studies exploring applications well beyond its approved diabetes and obesity indications. Published and ongoing research includes investigations into cardiovascular risk reduction, non-alcoholic fatty liver disease (NAFLD/NASH), chronic kidney disease, Alzheimer’s disease, and addiction disorders.
The research peptide form of semaglutide allows academic laboratories and independent researchers to study GLP-1 receptor biology, metabolic signaling, and incretin pharmacology without requiring pharmaceutical supply chains or clinical trial participation.
Emerging GLP-1 research comparisons. Researchers frequently compare semaglutide to other GLP-1 agonists including tirzepatide (a dual GIP/GLP-1 agonist), liraglutide (an earlier GLP-1 agonist with a shorter half-life), and the emerging triple agonist retatrutide (GLP-1/GIP/glucagon). Understanding semaglutide’s molecular properties is essential context for these comparative studies.
GLP-1 peptides face heightened regulatory scrutiny compared to other research peptides. In September 2025, the FDA issued warning letters to over 50 compounders and manufacturers of semaglutide and tirzepatide products, citing quality and manufacturing violations. The DOJ has pursued criminal charges against some sellers who made unauthorized therapeutic claims.
For research peptide vendors and purchasers, the key compliance points are clear: semaglutide must be labeled and sold strictly as a research compound (“for research use only”), therapeutic claims must never be made, and products must not be marketed as alternatives to FDA-approved medications. VMAX Peptides operates within these guidelines.
Researchers should also be aware that semaglutide’s regulatory landscape may continue to evolve as the FDA monitors the compounding and research peptide markets related to GLP-1 agonists.
Are peptides legal in 2026? Full regulatory breakdown
The active molecule (semaglutide) is the same, but the products are not identical. Ozempic is an FDA-approved pharmaceutical product manufactured under cGMP conditions with specific excipients, delivery devices, and clinical validation. Lyophilized semaglutide is a research peptide — the raw compound without the pharmaceutical formulation, regulatory approval, or quality infrastructure of the approved drug.
When reconstituted with bacteriostatic water and stored at 2–8°C (refrigerator), semaglutide remains stable for approximately 28 days. Do not freeze reconstituted semaglutide. For comparison, pharmaceutical Ozempic pens are used within 56 days of first use, but contain preservatives and stabilizers optimized for their specific formulation.
A GLP-1 receptor agonist is a compound that mimics the action of the natural hormone GLP-1 (glucagon-like peptide-1). When it binds to GLP-1 receptors, it stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system signaling. Semaglutide is one of several GLP-1 receptor agonists studied in research, along with tirzepatide, liraglutide, and the emerging compound retatrutide.
Lyophilized semaglutide is available for purchase as a research peptide without a prescription. However, it is sold for laboratory research purposes only. The FDA-approved pharmaceutical forms (Ozempic, Wegovy, Rybelsus) require a valid prescription from a licensed healthcare provider.
VMAX Peptides supplies lyophilized semaglutide at 99%+ HPLC-verified purity with mass spectrometry identity confirmation and third-party testing documentation. All orders include batch-specific Certificates of Analysis and are shipped with temperature-appropriate packaging.
Buy semaglutide research peptide
